Improving China's antiretroviral treatment program: assessing current and future performance using the principals of ethics
篇首： The global commitment to providing antiretroviral therapy (ART) to people living with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) in low-income countries has raised hope that the increasing momentum in the fight against the worldwide HIV/AIDS pandemic will be sufficient to control it. However, improved availability of subsidized antiretroviral (ARV) treatments in low-income countries raises complex ethical issues.1,2 In many resource-constrained countries the number of individuals infected with HIV in need of treatment far exceeds the supply of ARV medication. Resource allocation decisions can be made on the basis of many epidemiological,ethical, or preferential treatment priority criteria,Healthcare systems and funding in low-income countries are limited, requiring a step-by-step aipproach to scalingup programs to reach their stated aims.
|作 者||YIN Wen-yuan；ZHANG Fu-jie；Naomi Juniper；WU Zun-you|
|刊 名||中华医学杂志（英文版） 2009年122卷11期 1346-1351页|
|英文期刊名||CHINESE MEDICAL JOURNAL|
|关键词||acquired immunodeficiency syndrome antiretroviral treatment program ethics|